Dominick Kelli C, Wink Logan K, Pedapati Ernest V, Shaffer Rebecca, Sweeney John A, Erickson Craig A
1 Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.
2 Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati , Cincinnati, Ohio.
J Child Adolesc Psychopharmacol. 2018 May;28(4):274-278. doi: 10.1089/cap.2017.0057. Epub 2018 Feb 2.
The goal of this study was to assess the effectiveness of risperidone monoantipsychotic therapy targeting irritability in patients with Fragile X syndrome (FXS) in a naturalistic outpatient clinical setting.
We examined the use of risperidone, predominantly in combination with other nonantipsychotic psychotropic agents, targeting irritability in 21 male patients with FXS with a retrospective analysis of a prospectively collected large developmental disabilities-specific treatment database. Mean age at start of treatment, treatment duration, final dose, body mass index (BMI), and Clinical Global Impressions-Improvement (CGI-I) Scale score at final visit were determined, and changes with treatment were analyzed using paired t-tests.
Mean age at start of treatment was 14.0 years. The final mean dose of risperidone was 2.5 mg/day. The mean duration of treatment was 22 months. Seven (33.33%) participants were considered treatment responders based on the CGI-I. Change in BMI between initiation and cessation of treatment episode was not significant, however, these data were only available for a subset (n = 11) of patients.
Risperidone may be effective in the treatment of irritability in males with FXS. The overall effectiveness of monoantipsychotic treatment with risperidone was limited in this study compared with previous published reports; however, this may be the result of differences in outcome measures as well as a reflection of the level of functioning and severity of irritability in this sample.
本研究的目的是在自然主义的门诊临床环境中评估利培酮单一抗精神病药物治疗脆性X综合征（FXS）患者易怒症状的有效性。
我们通过对前瞻性收集的大型发育障碍特异性治疗数据库进行回顾性分析，研究了利培酮（主要与其他非抗精神病性精神药物联合使用）针对21例男性FXS患者易怒症状的使用情况。确定了治疗开始时的平均年龄、治疗持续时间、最终剂量、体重指数（BMI）以及末次随访时的临床总体印象改善（CGI-I）量表评分，并使用配对t检验分析治疗期间的变化。
治疗开始时的平均年龄为14.0岁。利培酮的最终平均剂量为2.5毫克/天。平均治疗持续时间为22个月。根据CGI-I，7名（33.33%）参与者被视为治疗有效者。治疗开始和结束期间BMI的变化不显著，然而，这些数据仅适用于部分患者（n = 11）。
利培酮可能对治疗FXS男性患者的易怒症状有效。与先前发表的报告相比，本研究中利培酮单一抗精神病药物治疗的总体有效性有限；然而，这可能是结果测量方法不同的结果，也反映了该样本的功能水平和易怒严重程度。
